ABSTRACT
Coronary artery disease [CAD] is a major killer across the world. The pathogenesis of CAD is a construct of multiple predisposing elements, including environmental, health and genetic factors. Traditional risk factors for CAD include age, hypertension, diabetes, smoking, and dyslipidaemia. Optimizing the lipid levels to within the normal range significantly and drastically reduces the risk of coronary atherosclerosis. Genome-wide association studies [GWASs] promise to accurately identifying the variants that increase or decrease the risks of multiple and complex disorders. In this review, we shed light on and discuss the recent GWASs of lipoprotein genetics and how such studies have provided new pathways and pharmacological targets that might enable the control the pathological plasma cholesterol levels